1. Home
  2. KZIA vs PYXS Comparison

KZIA vs PYXS Comparison

Compare KZIA & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kazia Therapeutics Limited

KZIA

Kazia Therapeutics Limited

SELL

Current Price

$5.61

Market Cap

125.6M

Sector

Health Care

ML Signal

SELL

Logo Pyxis Oncology Inc.

PYXS

Pyxis Oncology Inc.

SELL

Current Price

$1.42

Market Cap

141.3M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
KZIA
PYXS
Founded
1994
2018
Country
Australia
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
125.6M
141.3M
IPO Year
2002
2021

Fundamental Metrics

Financial Performance
Metric
KZIA
PYXS
Price
$5.61
$1.42
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
9
10
Target Price
★ $28.76
$8.22
AVG Volume (30 Days)
167.6K
★ 742.5K
Earning Date
11-27-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 3.03
EPS
★ N/A
N/A
Revenue
N/A
★ $13,858,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$4.86
$1.03
52 Week High
$17.40
$5.55

Technical Indicators

Market Signals
Indicator
KZIA
PYXS
Relative Strength Index (RSI) 26.35 29.90
Support Level $4.86 $1.29
Resistance Level $14.85 $1.77
Average True Range (ATR) 0.68 0.14
MACD -0.10 0.02
Stochastic Oscillator 2.75 0.87

Price Performance

Historical Comparison
KZIA
PYXS

About KZIA Kazia Therapeutics Limited

Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.

About PYXS Pyxis Oncology Inc.

Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.

Share on Social Networks: